CHEK2
CHEK2 (checkpoint kinase 2, also known as CHK2, CDS1 or HuCds1) is a nuclear serine/threonine kinase that regulates cell cycle checkpoints in response to DNA damage and replication blocks. It is a putative tumour suppressor and a member of the CHK2 subfamily of CAMK protein kinases. Browse Assay Genie's current range of CHEK2 research reagents below, or read on for the biology behind the target.
When cells experience DNA damage or replication blocks, cell cycle progression is halted through control of critical cell cycle regulators. CHEK2 is a cell cycle checkpoint regulator that is rapidly phosphorylated in these conditions. Its forkhead-associated protein interaction domain is essential for activation in response to DNA damage. Once active, the kinase inhibits CDC25C phosphatase, which prevents entry into mitosis, and it stabilises the tumour suppressor p53, leading to cell cycle arrest in G1.
CHEK2 also interacts with and phosphorylates BRCA1, allowing BRCA1 to restore survival after DNA damage. In the context of microbial infection, UniProt records that the kinase phosphorylates herpes simplex virus 1 protein ICP0 and thereby activates its SUMO-targeted ubiquitin ligase activity. The protein localises to the nucleus, including the nucleoplasm and PML bodies. It belongs to the protein kinase superfamily, in the CAMK Ser/Thr protein kinase family and CHK2 subfamily, and is classed by HGNC in the checkpoint kinase 2 family. The mouse ortholog is Chek2, and several transcript variants encoding different isoforms have been described for the human CHEK2 gene.
Mutations in CHEK2 have been linked with Li-Fraumeni syndrome, a highly penetrant familial cancer phenotype usually associated with inherited TP53 mutations. They are also thought to confer a predisposition to sarcomas, breast cancer and brain tumours. Earlier names reflect the S. pombe homologue, including CHK2 checkpoint homolog, and the symbols RAD53, PP1425 and bA444G7 appear among its aliases. CHEK1 is the related checkpoint kinase that works alongside CHEK2 in the DNA damage response.
CHEK2 is rapidly phosphorylated after DNA damage and replication blocks, making it a central readout of checkpoint activation.
Activated CHEK2 inhibits CDC25C to prevent mitotic entry and stabilises p53 to drive G1 arrest.
CHEK2 mutations are linked with Li-Fraumeni syndrome and thought to predispose to sarcomas, breast cancer and brain tumours.
CHEK2 phosphorylates BRCA1 to support survival after damage, and phosphorylates herpes simplex virus 1 ICP0 during infection.
CHEK2 is a checkpoint kinase activated by DNA damage and replication blocks. It inhibits CDC25C phosphatase to prevent entry into mitosis, stabilises p53 to cause G1 arrest, and phosphorylates BRCA1, which allows BRCA1 to restore survival after DNA damage.
CHEK2 is also called CHK2, CDS1, HuCds1, PP1425, bA444G7 and RAD53. Earlier HGNC names referred to the S. pombe homolog. UniProt calls the protein Serine/threonine-protein kinase Chk2, and several transcript variants encoding different isoforms are known.
Yes. Mutations in CHEK2 have been linked with Li-Fraumeni syndrome, a familial cancer phenotype usually associated with TP53 mutations. They are also thought to confer a predisposition to sarcomas, breast cancer and brain tumours. Mouse Chek2 is the corresponding ortholog; check the datasheet of any product for its validated reactivity.
Another checkpoint kinase involved in the DNA damage response, with products at Assay Genie.
Gene and protein annotations from HGNC, NCBI Gene and UniProt O96017; product specifications from Assay Genie datasheets.